• What We Do
  • Who We Are
  • Resources
  • News
  • GIVESMART

Search Results

NellOne Therapeutics utilizes ORNL’s “COVID-19 Rapid Access Licensing Program”

NellOne Therapeutics utilizes ORNL’s “COVID-19 Rapid Access Licensing Program”

by Bandera Admin | Nov 10, 2020 | News

The novel coronavirus is no doubt top of mind for most people with the infection numbers rising rapidly on a daily, so an announcement last week from Oak Ridge National Laboratory (ORNL) that involves a local early stage biopharmaceutical...
NellOne Therapeutics partners with ORNL on COVID-19 drug delivery system

NellOne Therapeutics partners with ORNL on COVID-19 drug delivery system

by Bandera Admin | Nov 5, 2020 | News

NellOne Therapeutics of Knoxville, Tenn., has licensed a drug delivery system from the Department of Energy’s Oak Ridge National Laboratory that is designed to transport therapeutics directly to cells infected by SARS-CoV-2, the virus causing COVID-19. The technology...
Anti-inflammatory molecules that treat cystic fibrosis may fight COVID-19

Anti-inflammatory molecules that treat cystic fibrosis may fight COVID-19

by Bandera Admin | Oct 27, 2020 | News

By Sarah Marshall, Uniformed Services University of the Health Sciences WASHINGTON — Efforts are underway at the Uniformed Services University of the Health Sciences to support the fight against the pandemic, including some that apply existing research and...
CEO Bill Malkes featured on Startup Knox Podcast

CEO Bill Malkes featured on Startup Knox Podcast

by Bandera Admin | Sep 22, 2020 | News

You don’t want to miss this interview by Brandon Bruce of Startup Knox with Knoxville serial entrepreneur Bill Malkes about his newest company NellOne Therapeutics. Click to view podcast on original website
NellOne Therapeutics secures key patent to revolutionize large-scale production

NellOne Therapeutics secures key patent to revolutionize large-scale production

by Bandera Admin | Aug 26, 2020 | News

NellOne Therapeutics Inc., the early stage biopharmaceutical company using a talented protein to plot a new future for regenerative medicine, today announced that the United States Patent and Trademark Office (“USPTO”) yesterday issued U.S. Patent No. 10,752,663 with...
« Older Entries

Categories

  • News
  • Resources

Recent Posts

  • NellOne Therapeutics utilizes ORNL’s “COVID-19 Rapid Access Licensing Program”
  • NellOne Therapeutics partners with ORNL on COVID-19 drug delivery system
  • Anti-inflammatory molecules that treat cystic fibrosis may fight COVID-19
  • CEO Bill Malkes featured on Startup Knox Podcast
  • NellOne Therapeutics secures key patent to revolutionize large-scale production
  • What We Do
  • Who We Are
  • Resources
  • News
  • GIVESMART

contact us



(865) 300-7161



hello@nell-one.com



11020 Solway School Rd

Knoxville, TN 37931

© NELLONE 2020 ALL RIGHTS RESERVED     |     SITE DESIGN BY BANDERA